Genentech Moves Rituxan Into Rheumatoid Arthritis, Readies Enbrel Supply
Executive Summary
Genentech's Rituxan rheumatoid arthritis development program has been added to the company's pipeline as its fourth R&D project for 2002
You may also be interested in...
Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005
The first supplemental BLA filing for Rituxan for the treatment of rheumatoid arthritis is slated for the fourth quarter of 2005, Roche Medical Science Department Head Guido Magni said
Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005
The first supplemental BLA filing for Rituxan for the treatment of rheumatoid arthritis is slated for the fourth quarter of 2005, Roche Medical Science Department Head Guido Magni said
Immunex/Genentech Enbrel Manufacturing Deal Will Expand Capacity In 2004
Genentech will be a second contract manufacturer for Immunex' Enbrel under an agreement between the two companies announced April 15